CULLINAN THERAPEUTICS INC (CGEM)
Health Care · Biotechnology · NASDAQ
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of targeted therapies for cancer and autoimmune diseases.
What CULLINAN THERAPEUTICS INC does
Cullinan Therapeutics is a biopharmaceutical company focused on developing a diverse pipeline of targeted oncology and autoimmune disease therapies. The company utilizes a risk-mitigated research and development strategy to advance clinical-stage product candidates aimed at addressing significant unmet medical needs.
Themes: oncology, autoimmune diseases, biotechnology, clinical-stage R&D
Fundamentals
- Price$15.46 as of 2026-10-08 close
- Market cap$995M as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return+139.7% 2025-10-08 close $6.45 → 2026-10-08 close $15.46
- P/En/a negative earnings
- ROE-53.8% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Beta1.03 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How CGEM compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CULLINAN THERAPEUTICS INC looks technically
CULLINAN THERAPEUTICS INC (CGEM) is trading 0.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 211 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 6 trading days ago. It is 33.3% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 0.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +0.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $19.31 | $19.31 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $15.42 | $15.42 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 18.51. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 211 trading days ago — a "golden cross", a bullish long-term signal | 211 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 0.2% above | +0.3% |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with sellers in control | 33.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30) | 35.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($14.20 to $21.88) — its "stochastic" reading is 16 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 16.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 26 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $23.19 | $23.19 |
|---|---|---|
| From the 52-week high | it is 33.3% below its 52-week high (its highest price of the past year) | -33.3% |
| Above the 52-week low | it is 172.2% above its 52-week low (its lowest price of the past year) | +172.2% |
| Below the 52-week high | it is 33.3% below its highest point of the past year | 33.3% |
| Since a 20-day breakout | it made a new 20-day low about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day low about 6 trading days ago | 6 sessions |
| All-time high | its highest closing price on record is $59.85 (set on 2021-03-10) | $59.85 |
| Given back of the 52-week move | over the past year its closes ranged ($5.84 to $22.95), and it has given back roughly a third of its rise from last year’s low — 44% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $11.83 to $12.38. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 43.8% |
| From the all-time high | it is 74.2% below its all-time high | -74.2% |
| Nearest price level | it is trading 2.8% below a resistance level at $15.89 — a price it turned at four times since 2026-04-08, most recently on 2026-08-03. Since 2024-10-08 it has 10 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.8% |
| All-time low | its lowest closing price on record is $5.68 (set on 2025-10-03) | $5.68 |
| Above the all-time low | it is 172.2% above its all-time low | +172.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 98% of the past ~6 months) | 98th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.19 between its high and its low — about 7.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.19 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $12.23 and $23.13 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $12.23 – $17.68 – $23.13 |
| Typical daily range (% of price) | its price moves about 7.7% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.7% |
| Stretch from the 200-day average | it is sitting essentially on its 200-day average price (0.3% above it in plain percentage terms) | at its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.99× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.2% |
|---|---|---|
| Gap filled | a 7.5% gap up opened on 2026-10-06 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -4.86% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 29.8 percentage points (the stock lost 28.7% while the market gained 1.0%) | -29.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 19.9 percentage points (the stock lost 16.1% while the market gained 3.8%) | -19.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 13.8 percentage points (the stock gained 3.6% while the market gained 17.5%) | -13.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 124.7 percentage points (the stock gained 139.7% while the market gained 15.0%) | +124.7% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 18% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 13.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -17.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 2% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $15.82 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -2.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 18% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $18.94 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -18.4% |
Price levels it has turned at before
CGEM last closed at $15.46 on 2026-10-08. Since 2024-10-08 it has turned at 10 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $15.89 | Resistance | 2.8% above the last close | turned there four times · 2026-04-08 to 2026-08-03 |
| $16.67 | Resistance | 7.8% above the last close | turned there three times · 2026-02-27 to 2026-05-29 |
| $13.77 | Support | 11.0% below the last close | turned there twice · 2024-12-02 to 2026-04-13 |
| $13.37 | Support | 13.5% below the last close | turned there three times · 2025-11-24 to 2026-05-19 |
| $13.03 | Support | 15.8% below the last close | turned there three times · 2025-01-03 to 2026-01-22 |
| $18.64 | Resistance | 20.6% above the last close | turned there twice · 2026-07-09 to 2026-09-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $18.51.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $16.01 and $18.04 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $14.20.
This reading has stood for 3 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Pulled back from the 12-month high · lagging the market · Just filled a gap (5%+ closed in the last week) · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.08 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$33.45 range $23.00 – $42.00; median $35.00
Analyst estimates, as of 2026-10-07. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CGEM
- Consensus EPS estimate-$0.8399 next reporting period, as of 2026-10-07
- Estimate change, 30 days+$0.00778 from -$0.8477, on 2026-09-02, 35-day window
- Readings revised upward25% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on clinical trial success and regulatory approval processes for product candidates.","Substantial operating losses and the need for significant additional capital to fund future operations.","Reliance on third-party partners for clinical trial conduct and drug manufacturing."]
What changed in the latest 10-Q
AI-assisted comparison of CGEM's 10-Q filed 2026-08-06 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
The two filings could not be meaningfully compared for this section.
Risk Factors
- Added:
- Newer filing adds description of CLN-978 as being developed for 'rheumatic diseases driven by pathogenic B cells' (older: 'autoimmune diseases').
- Newer filing adds that initial clinical data in SLE and RA were shared in a poster at EULAR, and additional clinical data including initial multi-dose regimen data in RA were shared at an investor event in June 2026.
- Newer filing adds plans to share additional multi-dose regimen data in RA and SLE in Q3 and Q4 2026 respectively, and to begin Phase 2 expansion in both disease areas by early 2027.
- Newer filing adds that velinotamig is being developed for 'autoimmune diseases driven by pathogenic autoantibodies produced by long-lived plasma cells' (older: 'autoimmune diseases').
- Newer filing adds that the Genrix trial is a 'Phase 1/2' clinical trial (older: 'Phase 1').
- Newer filing adds that initial clinical observations from two SLE patients with nephritis were shared in June 2026.
- Newer filing adds plans to initiate a global Phase 1/2 basket clinical trial in autoimmune cytopenias in early 2027.
- Newer filing adds that following a positive End-of-Phase 1 meeting with the U.S. FDA in July 2026, a potentially registrational Phase 2 trial in relapsed/refractory AML will be initiated in Q3 2026.
- Newer filing adds details of the CLN-049 Phase 2 study: dose-optimization phase with seamless progression to single-arm expansion cohort, and parallel exploratory cohort enrolling previously untreated TP53-mutated AML patients.
- Newer filing adds plan to initiate a Phase 1/2 clinical trial of CLN-049 combined with venetoclax and azacitidine as potential frontline treatment for previously untreated AML in Q4 2026.
- Newer filing adds 'an affiliate of' before Taiho in the zipalertinib NDA acceptance sentence.
- Newer filing adds a new sentence describing the April 2026 sales agreement with TD Securities (USA) LLC to continue the ATM program for up to $200.0 million of common stock.
- Removed:
- Older filing describes the company as developing 'high-impact therapies' for autoimmune diseases and cancer; newer filing replaces this with 'disease-modifying T cell engagers'.
- Older filing includes ASH 2025 monotherapy efficacy data disclosure for CLN-049; newer filing omits this sentence.
- Older filing states dose level expansion continues to determine recommended Phase 2 dose by Q4 2026 for a potential single-arm pivotal registrational trial; newer filing omits this sentence and replaces with Phase 2 initiation details.
- Older filing includes a sub-bullet stating Taiho shared emerging data from certain REZILIENT2 cohorts at medical conferences in 2025; newer filing omits this.
- Older filing includes a paragraph with financial details as of March 31, 2026: cash, cash equivalents and short-term investments of $351.9 million, long-term investments and interest receivable of $41.4 million, accumulated deficit of $637.8 million, and statements about operating losses, negative cash flows, and future viability; newer filing omits this paragraph.
- Reworded:
- Newer filing changes 'Immunology' heading to 'Immunology Pipeline' and 'Oncology' heading to 'Oncology Pipeline'.
- Newer filing states zipalertinib is designed to 'selectively target cells expressing EGFR exon 20 insertion mutations' with relative sparing of wild-type EGFR; older filing omits the word 'selectively' in that sentence.
- Newer filing states 'The U.S. FDA assigned a Prescription Drug User Fee Act target action date of February 27, 2027'; older filing states 'The Prescription Drug User Fee Act target action date is February 27, 2027'.
- Newer filing combines the zipalertinib NDA acceptance and supporting data into one sentence; older filing presents them as separate sub-bullets.
- Newer filing states Taiho completed enrollment in February 2026 and expects top-line results by end of 2026 in the same item; older filing states this in a separate sub-bullet for REZILIENT3.
- Newer filing states 'We hold worldwide intellectual property rights for CLN-978' (older: 'We hold the worldwide intellectual property rights for CLN-978').
- Newer filing states 'We hold worldwide, excluding mainland China...' (older: 'We hold the worldwide, excluding mainland China...').
- Newer filing states 'We hold worldwide intellectual property rights for CLN-049' (older: 'We hold the worldwide intellectual property rights for CLN-049').
- Newer filing states 'for which Taiho holds intellectual property rights' (older: 'for which Taiho holds the intellectual property rights').
- Newer filing updates ownership interest reference date from March 31, 2026 to June 30, 2026.
- Newer filing states 'We have received $18.9 million in revenue from a previous license agreement and cash proceeds of $275.0 million from the sale of our equity interest...'; older filing states 'We have received $275.0 million in revenue from a previous license agreement and cash proceeds of $18.9 million from the sale...' (amounts are swapped between revenue and cash proceeds).
- Newer filing omits 'cash proceeds of' before the $275.0 million figure and refers to it as from the sale of equity interest in the former zipalertinib development subsidiary.
- Newer filing appears truncated mid-sentence at 'We ma' in the ATM program description; older filing does not contain this ATM agreement description.
- Notes:
- The newer filing text ends mid-sentence at 'We ma' and may be truncated, so changes after that point cannot be assessed.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 2 sells ($780360) — 1 selling insider
- Last 180 days · read to 2026-10-040 buys · 5 sells ($1M) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-08. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CGEM's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CGEM as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 10,494,687
- Reported value $191,108,244
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CGEM's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CGEM had 9,629,017 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CGEM had 15.0% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 10.88 days to cover at the same settlement.
- Reported short interest (shares) 9,629,017
- Short interest (% of shares outstanding) 15.0%
- Prior settlement (shares) 10,371,763
- Reported change -7.16%
- Days to cover (reported) 10.88
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- Bristol Myers Squibb (BMY)
- Merck & Co. (MRK)
- Novartis (NVS)
- Gilead Sciences (GILD)
- Seagen (now part of Pfizer) (PFE)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CGEM vs…
CULLINAN THERAPEUTICS INC is found in…
Frequently asked questions
What does CULLINAN THERAPEUTICS INC (CGEM) do?
Cullinan Therapeutics is a biopharmaceutical company focused on developing a diverse pipeline of targeted oncology and autoimmune disease therapies. The company utilizes a risk-mitigated research and development strategy to advance clinical-stage product candidates aimed at addressing significant unmet medical needs.
What sector is CULLINAN THERAPEUTICS INC (CGEM) in?
CULLINAN THERAPEUTICS INC (CGEM) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are CULLINAN THERAPEUTICS INC's (CGEM) competitors?
Notable peers of CULLINAN THERAPEUTICS INC (CGEM) include Amgen, Bristol Myers Squibb, Merck & Co., Novartis and Gilead Sciences. This peer set is informational only — not financial advice.
Is CULLINAN THERAPEUTICS INC (CGEM) overbought or oversold right now?
CULLINAN THERAPEUTICS INC (CGEM) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 35, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CGEM come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.